A novel nanoparticle formulation overcomes multiple types of membrane efflux pumps in human breast cancer cells

Drug Delivery and Translational Research
Preethy PrasadXiao Yu Wu

Abstract

Multidrug resistance (MDR) in cancer cells can involve overexpression of different types of membrane drug efflux pumps and other drug resistance mechanisms. Hence, inhibition of one resistance mechanism may not be therapeutically effective. Previously we demonstrated a new polymer lipid hybrid nanoparticle (PLN) system was able to circumvent drug resistance of P-glycoprotein (P-gp) overexpressing breast cancer cells. The objectives of the present study were 2-fold: (1) to evaluate the ability of the PLN system to overcome two other membrane efflux pumps-multidrug resistance protein 1 (MRP1+) and breast cancer resistance protein (BCRP+) overexpressed on human breast cancer cell lines MCF7 VP (MRP1+) and MCF7 MX (BCRP+); and (2) to evaluate possible synergistic effects of doxorubicin (Dox)-mitomycin C (MMC) in these cell lines. These objectives were accomplished by measuring in vitro cellular uptake, intracellular trafficking, and cytotoxicity (using a clonogenic assay and median effect analysis), of Dox, MMC, or Dox-MMC co-loaded PLN. Treatment of MDR cells with PLN encapsulating single anticancer agents significantly enhanced cell kill compared to free Dox or MMC solutions. Dox-MMC co-loaded PLN were 20-30-folds more effective ...Continue Reading

References

Jan 1, 1992·Annual Review of Cell Biology·C F Higgins
Jan 1, 1989·Annual Review of Biochemistry·J A Endicott, V Ling
Nov 1, 1973·Journal of the National Cancer Institute·H D SouleM Brennan
May 1, 1993·British Journal of Cancer·M J MillwardA L Harris
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·L A DoyleD D Ross
Dec 23, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R StuppS Leyvraz
Dec 3, 1999·Biochimica Et Biophysica Acta·P BorstJ Wijnholds
May 16, 2000·Biochemical Pharmacology·A Astriab-FisherR L Juliano
Sep 6, 2000·British Journal of Haematology·R J Arceci
Oct 18, 2000·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·R Krishna, L D Mayer
Jan 6, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D BelpommeF Sturtz
May 11, 2001·Japanese Journal of Cancer Research : Gann·A KanzakiY Takebayashi
Jan 31, 2002·Annual Review of Medicine·Michael M Gottesman
Feb 8, 2002·Cancer Metastasis Reviews·I F Tannock
Mar 21, 2002·Nature Reviews. Cancer·Michael M GottesmanSusan E Bates
Jun 8, 2002·Breast Cancer Research : BCR·John W Park
Sep 3, 2002·Advanced Drug Delivery Reviews·Irène BriggerPatrick Couvreur
Nov 15, 2002·Cancer Biology & Therapy·Wafik S El-Deiry
Jan 22, 2003·Advanced Drug Delivery Reviews·Alfred H Schinkel, Johan W Jonker
Apr 29, 2003·Journal of Cardiovascular Electrophysiology·Sabine C M EijsboutsMaurits A Allessie
Oct 25, 2003·Oncogene·Gary D Kruh, Martin G Belinsky
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter L GreenbergJacob M Rowe
Jul 22, 2004·Molecular Pharmacology·Dong XuR L Juliano
Aug 13, 2005·Advances in Cancer Research·Kristina ViktorssonBoris Zhivotovsky
Nov 25, 2005·Current Drug Delivery·Hristos GlavinasBalázs Sarkadi
Jul 18, 2006·Current Drug Targets·S NobiliE Mini
Nov 14, 2006·Journal of Controlled Release : Official Journal of the Controlled Release Society·Ho Lun WongXiao Yu Wu
Dec 13, 2006·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Ho Lun WongXiao Yu Wu
Feb 1, 2007·Nucleic Acids Research·Michael FisherPiet Herdewijn
Feb 27, 2007·Cancer Metastasis Reviews·Robert W RobeySusan E Bates
Feb 9, 2008·Pharmacology·Howard R Mellor, Richard Callaghan
Feb 15, 2008·Proceedings of the National Academy of Sciences of the United States of America·Frank GuOmid C Farokhzad
May 2, 2008·Drug Metabolism and Drug Interactions·Adam J ShuhendlerXiao Yu Wu
Jun 10, 2008·Cancer Treatment Reviews·Lara S Jabr-MilaneMansoor M Amiji
Feb 15, 2012·International Journal of Breast Cancer·N S Wind, I Holen

❮ Previous
Next ❯

Citations

Aug 28, 2015·Expert Review of Anticancer Therapy·Iben KümlerDorte Lisbet Nielsen
Sep 22, 2012·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Alireza ShalviriXiao Yu Wu
Mar 16, 2016·Expert Opinion on Drug Delivery·Xiao Yu Wu
May 10, 2016·International Journal of Biological Macromolecules·Huaxi XiaoYuejiao Chen
Jun 12, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Rui Xue ZhangXiao Yu Wu
Nov 5, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yousheng ZhouXiao Yu Wu
Mar 27, 2020·Frontiers in Pharmacology·Shengdi GuoWuli Yang
Jul 16, 2019·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Yulin WangThomas Efferth
May 6, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Marta SzumilakAndrzej Stanczak
Jun 8, 2021·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Tengteng ZouYu Cai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.